CA1316108C - Formulation for preparing sustained release drugs for oral administration - Google Patents

Formulation for preparing sustained release drugs for oral administration

Info

Publication number
CA1316108C
CA1316108C CA000531406A CA531406A CA1316108C CA 1316108 C CA1316108 C CA 1316108C CA 000531406 A CA000531406 A CA 000531406A CA 531406 A CA531406 A CA 531406A CA 1316108 C CA1316108 C CA 1316108C
Authority
CA
Canada
Prior art keywords
tablets
release
xanthan gum
matrix
sustained release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA000531406A
Other languages
English (en)
French (fr)
Inventor
Massimo Calanchi
Marco Marconi
Luigi Mapelli
Leonardo Gentilini
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Eurand Italia SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11160299&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA1316108(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eurand Italia SpA filed Critical Eurand Italia SpA
Application granted granted Critical
Publication of CA1316108C publication Critical patent/CA1316108C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA000531406A 1986-03-07 1987-03-06 Formulation for preparing sustained release drugs for oral administration Expired - Fee Related CA1316108C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT19675/86A IT1191674B (it) 1986-03-07 1986-03-07 Formulazioni per la preparazione di farmaci a rilascio prolungato adatte alla somministrazione per via orale
IT19675A/86 1986-03-07

Publications (1)

Publication Number Publication Date
CA1316108C true CA1316108C (en) 1993-04-13

Family

ID=11160299

Family Applications (1)

Application Number Title Priority Date Filing Date
CA000531406A Expired - Fee Related CA1316108C (en) 1986-03-07 1987-03-06 Formulation for preparing sustained release drugs for oral administration

Country Status (12)

Country Link
US (1) US5047248A (ja)
EP (1) EP0261213B1 (ja)
JP (1) JP2617109B2 (ja)
KR (1) KR880701099A (ja)
CA (1) CA1316108C (ja)
DK (1) DK172117B1 (ja)
HK (1) HK12395A (ja)
IT (1) IT1191674B (ja)
NZ (1) NZ219523A (ja)
PT (1) PT84416B (ja)
WO (1) WO1987005212A1 (ja)
ZA (1) ZA871620B (ja)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601204D0 (en) * 1986-01-18 1986-02-19 Boots Co Plc Therapeutic agents
US4994276A (en) * 1988-09-19 1991-02-19 Edward Mendell Co., Inc. Directly compressible sustained release excipient
US5096714A (en) * 1988-06-28 1992-03-17 Hauser-Kuhrts, Inc. Prolonged release drug tablet formulations
US5128143A (en) * 1988-09-19 1992-07-07 Edward Mendell Co., Inc. Sustained release excipient and tablet formulation
US5169639A (en) * 1988-09-19 1992-12-08 Edward Mendell Co., Inc. Controlled release verapamil tablets
US5032406A (en) * 1989-02-21 1991-07-16 Norwich Eaton Pharmaceuticals, Inc. Dual-action tablet
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5292534A (en) * 1992-03-25 1994-03-08 Valentine Enterprises, Inc. Sustained release composition and method utilizing xanthan gum and an active ingredient
US5298261A (en) * 1992-04-20 1994-03-29 Oregon Freeze Dry, Inc. Rapidly distintegrating tablet
NL9201195A (nl) * 1992-07-03 1994-02-01 Tno Preparaat voor de gereguleerde afgifte van een werkzame stof en werkwijze ter bereiding van een dergelijk preparaat.
US5472711A (en) * 1992-07-30 1995-12-05 Edward Mendell Co., Inc. Agglomerated hydrophilic complexes with multi-phasic release characteristics
US5399354A (en) * 1993-05-28 1995-03-21 Mcneil-Ppc, Inc. Process for making a hard-candy based oral pharmaceutical lozenge containing an antacid
US5993860A (en) * 1993-06-17 1999-11-30 Venture Lending NSADI delivery employing a powdered hydrocolloid gum obtainable from higher plants
US6129930A (en) 1993-09-20 2000-10-10 Bova; David J. Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night
US6080428A (en) 1993-09-20 2000-06-27 Bova; David J. Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
US6746691B2 (en) 1993-09-20 2004-06-08 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics
US6676967B1 (en) 1993-09-20 2004-01-13 Kos Pharmaceuticals, Inc. Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia
US6818229B1 (en) 1993-09-20 2004-11-16 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia
FR2729857B1 (fr) * 1995-01-27 1997-04-04 Rhone Poulenc Chimie Compositions pharmaceutiques sous forme de comprimes a liberation prolongee a base de granules en polysaccharides de haut poids moleculaire
BE1009380A3 (nl) * 1995-03-14 1997-03-04 Universiteit Gent Lab Voor Far Stabiliserend samenstelling voor suspensie.
AU2068797A (en) * 1996-01-29 1997-08-20 Edward Mendell Co. Inc. Sustained release excipient
US6210710B1 (en) * 1997-04-28 2001-04-03 Hercules Incorporated Sustained release polymer blend for pharmaceutical applications
IN186245B (ja) 1997-09-19 2001-07-14 Ranbaxy Lab Ltd
DE69940557D1 (de) * 1998-12-11 2009-04-23 Nostrum Pharmaceuticals Inc Ein hydrokolloid und einen celluloseether enthaltende tablette mit verzögerter freisetzung
CZ2002336A3 (cs) * 1999-07-30 2002-06-12 Smithkline Beecham Plc Multikomponentní farmaceutická dávková forma
WO2001021259A2 (en) * 1999-09-21 2001-03-29 Emory University Use and compositions for treating platelet-related disorders using anagrelide
US8012504B2 (en) * 2000-04-28 2011-09-06 Reckitt Benckiser Inc. Sustained release of guaifenesin combination drugs
US6955821B2 (en) * 2000-04-28 2005-10-18 Adams Laboratories, Inc. Sustained release formulations of guaifenesin and additional drug ingredients
US6372252B1 (en) 2000-04-28 2002-04-16 Adams Laboratories, Inc. Guaifenesin sustained release formulation and tablets
US7985420B2 (en) * 2000-04-28 2011-07-26 Reckitt Benckiser Inc. Sustained release of guaifenesin combination drugs
US7838032B2 (en) * 2000-04-28 2010-11-23 Reckitt Benckiser Inc. Sustained release of guaifenesin
US7276250B2 (en) * 2001-07-06 2007-10-02 Penwest Pharmaceuticals Company Sustained release formulations of oxymorphone
CA2452872A1 (en) * 2001-07-06 2003-01-16 Endo Pharmaceuticals, Inc. Parenteral administration of 6-hydroxy-oxymorphone for use as an analgesic
US8329216B2 (en) 2001-07-06 2012-12-11 Endo Pharmaceuticals Inc. Oxymorphone controlled release formulations
US20040052851A1 (en) * 2002-09-16 2004-03-18 Graff Allan H. Modified release oral dosage form
EP2112920B1 (en) 2003-06-26 2018-07-25 Intellipharmaceutics Corp. Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
AP1899A (en) 2003-08-08 2008-10-10 Biovail Lab Int Srl Modified-release tablet of bupropion hydrochloride
GB0320854D0 (en) 2003-09-05 2003-10-08 Arrow No 7 Ltd Buccal drug delivery
US20050053648A1 (en) * 2003-09-08 2005-03-10 Chalmers Anne Marie Medication delivery device
US8394409B2 (en) 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
AU2006269944A1 (en) * 2005-07-19 2007-01-25 Inverseon, Inc. Improved pharmacokinetic profile of beta-adrenergic inverse agonists for the treatment of pulmonary airway diseases
CN101304764B (zh) 2005-11-11 2012-12-05 旭化成化学株式会社 控释固体制剂
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
CA2648280C (en) 2006-04-03 2014-03-11 Isa Odidi Controlled release delivery device comprising an organosol coat
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
US20080220064A1 (en) * 2006-12-06 2008-09-11 Ramesh Ketkar Anant Extended release matrix formulations of morphine
GB2460915B (en) 2008-06-16 2011-05-25 Biovascular Inc Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor
US20120065221A1 (en) 2009-02-26 2012-03-15 Theraquest Biosciences, Inc. Extended Release Oral Pharmaceutical Compositions of 3-Hydroxy-N-Methylmorphinan and Method of Use
EP2544667B1 (en) * 2010-03-09 2018-11-14 Alkermes Pharma Ireland Limited Alcohol resistant enteric pharmaceutical compositions
WO2014014645A1 (en) * 2012-07-17 2014-01-23 Miranda Technologies, Inc. Systems and methods for oral administration of a therapy
WO2017052455A1 (en) 2015-09-23 2017-03-30 Anara Ab Amylase fragments for blood glucose control
CA3001337C (en) 2015-10-09 2023-12-12 Reckitt Benckiser Llc Pharmaceutical formulation
EP3251687A1 (en) 2016-06-01 2017-12-06 Centrum Innowacji Edoradca Sp. z o.o. Spolka Komandytowa Bioactive peptides for blood glucose control

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3065143A (en) * 1960-04-19 1962-11-20 Richardson Merrell Inc Sustained release tablet
DE2130545A1 (de) * 1971-06-19 1972-12-21 Merck Patent Gmbh Pharmazeutischer Formkoerper
US4332789A (en) * 1975-12-15 1982-06-01 Hoffmann-La Roche Inc. Pharmaceutical unit dosage forms
US4344857A (en) * 1975-12-22 1982-08-17 The United States Of America As Represented By The Secretary Of Agriculture Encapsulation by entrapment
US4163777A (en) * 1977-04-29 1979-08-07 Lewis/Howe Company Controlled antacid delivery form and method of treatment therewith
US4259341A (en) * 1977-06-01 1981-03-31 Merck & Co., Inc. Di- and tri-substituted thiazoles
US4248858A (en) * 1979-08-09 1981-02-03 American Home Products Corporation Sustained release pharmaceutical compositions
US4375468A (en) * 1981-07-13 1983-03-01 Verex Laboratories, Inc. Constant order release aspirin composition and method of treating arthritis
US4369172A (en) * 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
US4556678A (en) * 1982-06-24 1985-12-03 Key Pharmaceuticals, Inc. Sustained release propranolol tablet
DE3346571A1 (de) * 1983-12-23 1985-07-04 Bayer Ag, 5090 Leverkusen Oral retardierte acetylsalicylsaeureformulierungen
JPS60174728A (ja) * 1984-02-22 1985-09-09 Sato Seiyaku Kk 持効性製剤
JPS6124516A (ja) * 1984-07-12 1986-02-03 Fujisawa Pharmaceut Co Ltd 持続性錠剤
US4610870A (en) * 1984-10-05 1986-09-09 E. R. Squibb & Sons, Inc. Controlled release formulation
GB8426152D0 (en) * 1984-10-16 1984-11-21 Reckitt & Colmann Prod Ltd Medicinal compositions
DE3440288A1 (de) * 1984-11-05 1986-05-07 Gergely, Gerhard, Dr.-Ing., Wien Pharmazeutische zubereitung mit einem gehalt an mindestens einer schleimhautreizenden substanz oder dergleichen, insbesondere profen, sowie verfahren zu ihrer herstellung
BE901111A (fr) * 1984-11-22 1985-03-15 Benfar Representee Par Vanderl Composition pharmaceutiques a liberation prolongee, leur procede de preparation et leur utilisation.
SE8501094D0 (sv) * 1985-03-06 1985-03-06 Ulf Schroder Biologiskt aktiv komposition och forfarande for framstellning derav
GB8507779D0 (en) * 1985-03-26 1985-05-01 Fujisawa Pharmaceutical Co Drug carrier
US4704285A (en) * 1985-11-18 1987-11-03 The Dow Chemical Company Sustained release compositions comprising hydroxypropyl cellulose ethers
GB8601204D0 (en) * 1986-01-18 1986-02-19 Boots Co Plc Therapeutic agents

Also Published As

Publication number Publication date
JP2617109B2 (ja) 1997-06-04
DK582287A (da) 1987-11-05
IT1191674B (it) 1988-03-23
DK582287D0 (da) 1987-11-05
IT8619675A0 (it) 1986-03-07
KR880701099A (ko) 1988-07-25
PT84416A (en) 1987-04-01
EP0261213B1 (en) 1992-08-05
NZ219523A (en) 1990-08-28
AU603098B2 (en) 1990-11-08
IT8619675A1 (it) 1987-09-07
EP0261213A1 (en) 1988-03-30
AU7288387A (en) 1987-09-28
DK172117B1 (da) 1997-11-17
PT84416B (pt) 1989-10-04
WO1987005212A1 (en) 1987-09-11
US5047248A (en) 1991-09-10
HK12395A (en) 1995-02-03
ZA871620B (en) 1988-02-24
JPS63503225A (ja) 1988-11-24

Similar Documents

Publication Publication Date Title
CA1316108C (en) Formulation for preparing sustained release drugs for oral administration
US5169638A (en) Buoyant controlled release powder formulation
KR100205276B1 (ko) 서방성 정제
CA1054056A (en) Solid therapeutic preparation remaining in stomach
CA2016039C (en) Extended release pharmaceutical formulations
CA1331344C (en) Sustained release drug dosage forms containing hydroxypropylmethylcellulose and alkali metal carboxylates
JP4077886B2 (ja) 不溶性薬剤の持効性ヘテロ分散ヒドロゲル系
JP3382950B2 (ja) 医薬品用の徐放性マトリックス
US4375468A (en) Constant order release aspirin composition and method of treating arthritis
FI113336B (fi) Menetelmä tramadolisuolaa sisältävän lääkeaineen valmistamiseksi, jolla on viivästynyt vaikuttavan aineen vapautuminen
JPH01250314A (ja) 徐放性製剤
JPS61246120A (ja) 浮遊、持続放出性治療用組成物
EP0211991B1 (en) Substained release tablets and method for preparation thereof
IE912885A1 (en) Multiparticulate sustained release matrix system
US4547358A (en) Sustained release tablet containing at least 95 percent theophylline
EP0840598A1 (en) Alkalinizing potassium salt controlled release preparations
DE60319983T2 (de) Universelle Zusammensetzung zur kontrollierten Wirkstoffabgabe enthaltend Chitosan
EP0484106A1 (en) Controlled release formulations
AU603098C (en) Formulation for preparing sustained released drugs
CA2205351A1 (en) Sustained-release drug delivery employing a powdered hydrocolloid gum obtainable from higher plants
EP0866707A1 (en) Cisapride sustained release
EP0547688B1 (en) Sustained release tablets
DE3780893T2 (de) Formulierung zur herstellung von arzneimitteln mit verzoegerter freisetzung zur oralen gabe.
GB2078518A (en) Sustained release theophylline tablet having reduced bulk
CA1269043A (en) Floating sustained release therapeutic compositions

Legal Events

Date Code Title Description
MKLA Lapsed